SCHEMBL4010374

SCHEMBL4010374

CCCCC(C)C[C@@H](CC(=O)O)NC(=O)[C@@H](N)CC(C)C

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PLA2G10 O15496 3/20 0.44
DPP7 Q9UHL4 11/20 0.40
DPP9 Q86TI2 9/20 0.40
DPP8 Q6V1X1 9/20 0.40
DPP4 P27487 6/20 0.40
SLC15A1 P46059 1/20 0.40
SLC1A3 P43003 1/20 0.38
SLC1A2 P43004 1/20 0.38
SLC1A1 P43005 1/20 0.38
SLC7A5 Q01650 1/20 0.38
CACNA2D1 P54289 2/20 0.37
CACNB3 P54284 1/20 0.37
CACNA1C Q13936 1/20 0.37
PGR P06401 1/20 0.37
ADRA1A P35348 1/20 0.37
HTR2B P41595 1/20 0.37
CACNA2D2 Q9NY47 1/20 0.37
PDF Q9HBH1 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4014269 1.00 PLA2G10 (0.44) PLA2G10DPP7DPP9DPP8DPP4
SCHEMBL4008872 1.00 PLA2G10 (0.44) PLA2G10DPP7DPP9DPP8DPP4
SCHEMBL4010441 1.00 PLA2G10 (0.44) PLA2G10DPP7DPP9DPP8DPP4
SCHEMBL4014987 0.92 PLA2G10 (0.40) PLA2G10DPP7DPP9DPP8DPP4
SCHEMBL4006234 0.92 PLA2G10 (0.40) PLA2G10DPP7DPP9DPP8DPP4
SCHEMBL4008803 0.92 PLA2G10 (0.40) PLA2G10DPP7DPP9DPP8DPP4
SCHEMBL4009543 0.92 PLA2G10 (0.40) PLA2G10DPP7DPP9DPP8DPP4
SCHEMBL4011955 0.87 DPP7 (0.50) PLA2G10DPP7DPP9DPP8DPP4
SCHEMBL4007878 0.87 DPP7 (0.50) PLA2G10DPP7DPP9DPP8DPP4
SCHEMBL4015153 0.87 DPP7 (0.50) PLA2G10DPP7DPP9DPP8DPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7491835-B2 Prodrugs of amino acids with affinity for the α2δ-protein PFIZER INC (US) 2009-02-17 US claimed
EP-1670750-A1 PRODRUGS OF AMINO ACIDS WITH AFFINITY FOR THE ALPHA2DELTA- PROTEIN Warner-Lambert Company LLC (US) 2006-06-21 EP claimed
WO-2005030703-A1 PRODRUGS OF AMINO ACIDS WITH AFFINITY FOR THE α2δ- PROTEIN WARNER-LAMBERT COMPANY LLC (US) 2005-04-07 WO claimed
US-20050070483-A1 Prodrugs of amino acids with affinity for the alpha2delta-protein VIATRIS SPECIALTY LLC. 2005-03-31 US claimed
US-7491835-B2 Prodrugs of amino acids with affinity for the α2δ-protein PFIZER INC (US) 2009-02-17 US disclosed
EP-1670750-A1 PRODRUGS OF AMINO ACIDS WITH AFFINITY FOR THE ALPHA2DELTA- PROTEIN Warner-Lambert Company LLC (US) 2006-06-21 EP disclosed
WO-2005030703-A1 PRODRUGS OF AMINO ACIDS WITH AFFINITY FOR THE α2δ- PROTEIN WARNER-LAMBERT COMPANY LLC (US) 2005-04-07 WO disclosed
US-20050070483-A1 Prodrugs of amino acids with affinity for the alpha2delta-protein VIATRIS SPECIALTY LLC. 2005-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050070483-A1 Prodrugs of amino acids with affinity for the alpha2delta-protein SCN2A, OPRD1, SCN1A PLA2G10 2762/4885DPP7 1105/4885DPP9 2414/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.